Juan Gómez Rivas, Associate Professor at The Complutense University of Madrid, posted on X about recent paper by him as first author, titled “Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer” published on MDPI.
Authors: Juan Gómez Rivas, Luis Enrique Ortega Polledo, Irene De La Parra Sánchez, Beatriz Gutiérrez Hidalgo, Javier Martín Monterrubio, María Jesús Marugán Álvarez, Bhaskar K. Somani, Dmitry Enikeev, Javier Puente Vázquez, Noelia Sanmamed Salgado, María Isabel Galante Romo, Jesús Moreno Sierra
“Neoadjuvant Therapy in High-Risk Localized Prostate Cancer: What’s New?
Key Takeaways: High-risk localized prostate cancer has higher chances of recurrence and progression compared to low/intermediate risk.
Androgen deprivation therapy (ADT) reduces tumor size but shows no survival benefit.
Second-generation agents (like ARPIs) are showing promise in improving survival outcomes in trials.
Highlights from the Review:
- Guideline Status: Neoadjuvant therapy is not yet standard care, recommended only within clinical trials.
- Promising Trials: Phase II studies suggest better pathological outcomes and lower relapse rates with ADT + ARPIs.
- Future Directions: Innovative therapies like Lu-177 PSMA and genomics-based treatments hold potential for personalized care.
What’s Next?: More robust Phase III trials are needed to solidify these therapies as game-changers!
For clinicians and researchers: The focus remains on improving biomarkers and identifying patients who will benefit most.”